Insmed reported $1.63B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
DBV Technologies USD 201.9M 44.8M Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026